BioCentury | Mar 16, 2021
Politics, Policy & Law

FTC’s ‘aggressive’ new approach to pharma merger regulation will include biotech M&A

...importantly have access to them at prices that they can afford.”Michael Carrier, a professor at Rutgers University...
...change its rules so much that the entire business model is at risk.” Michael Carrier, Rutgers University...
BioCentury | Jan 1, 2021
Targets & Mechanisms

A snapshot of target innovation in 2020

...of Calgary, and the SCNA mRNA-binding compound from Rutgers University...
...George Washington University Chinese Academy of Sciences University of Calgary Rutgers University Queen...
BioCentury | Nov 21, 2020
Finance

Mei readies Antengene to take its next steps to becoming a global biotech

...was a chemist with a Ph.D. from Rutgers University...
BioCentury | May 9, 2020
Product Development

FDA authorizes first COVID-19 test using at-home saliva samples, begins unveiling serological test validation data

...FDA’s authorization of a COVID-19 diagnostic from Rutgers University marks the first time the agency has signed...
...coronavirus crisis can be found at https://www.biocentury.com/coronavirus Karen Tkach Tuzman, Associate Editor U.S. Food and Drug Administration (FDA) Rutgers University Sherlock...
BioCentury | Apr 14, 2020
Product Development

COVID-19 roundup: Can-Fite repurposing RA therapy; plus Brazilian chloroquine study points to cardiotoxicity, Athersys stem cell trial, Rutgers saliva test

...Rutgers spit test authorized FDA granted Emergency Use Authorization (EUA) to a COVID-19 test from Rutgers University...
...receptor Elizabeth S. Eaton, Staff Writer and Sandi Wong, Assistant Editor MultiStem (Multipotent adult progenitor cells (MAPC)) Athersys Inc. Rutgers University Can-Fite...
BioCentury | Feb 1, 2020
Distillery Therapeutics

SNCA mRNA-binding compound for Parkinson's

...Natl. Acad. Sci. USA ; published online Jan. 3, 2020 doi:10.1073/pnas.1905057117 CONTACT: M. Maral Mouradian, Rutgers University...
...N.J. email: m.mouradian@rutgers.edu CONTACT: Matthew D. Disney, The Scripps Research Institute, Jupiter, Fla. email: disney@scripps.edu Claire Quang Rutgers University Scripps...
BioCentury | Jan 30, 2020
Distillery Therapeutics

Flu vaccines as a cancer immunotherapies

...CONTACT: Andrew Zloza, Rush University Medical Center, Chicago, Ill.; Rutgers University, New Brunswick, N.J. email: Andrew_Zloza@rush.edu Claire Quang Rutgers University Rush...
BioCentury | Feb 9, 2019
Company News

Emerging company roundup: HiberCell, Orexia, TamRx

...from pharmaceutical accelerator BioMotiv LLC. The cancer immunotherapy company, which is based on research from Rutgers University...
BioCentury | Feb 8, 2019
Company News

BioMotiv, Rutgers launch TamRx

...the clinic with its pan-TAM inhibitors in 2021. The company is based on research from Rutgers University...
...TYRO3 protein tyrosine kinase TamRx LLC, Cleveland, Ohio BioMotiv LLC, Cleveland, Ohio Business: Cancer Mark Zipkin BioMotiv LLC Rutgers University AXL...
BioCentury | Feb 7, 2019
Company News

BioMotiv, Rutgers launch TamRx

...the clinic with its pan-TAM inhibitors in 2021. The company is based on research from Rutgers University...
...6; MERTK - c-Mer proto-oncogene tyrosine kinase; TYRO3 (Sky) - TYRO3 protein tyrosine kinase Mark Zipkin BioMotiv LLC Rutgers University AXL...
Items per page:
1 - 10 of 79
BioCentury | Mar 16, 2021
Politics, Policy & Law

FTC’s ‘aggressive’ new approach to pharma merger regulation will include biotech M&A

...importantly have access to them at prices that they can afford.”Michael Carrier, a professor at Rutgers University...
...change its rules so much that the entire business model is at risk.” Michael Carrier, Rutgers University...
BioCentury | Jan 1, 2021
Targets & Mechanisms

A snapshot of target innovation in 2020

...of Calgary, and the SCNA mRNA-binding compound from Rutgers University...
...George Washington University Chinese Academy of Sciences University of Calgary Rutgers University Queen...
BioCentury | Nov 21, 2020
Finance

Mei readies Antengene to take its next steps to becoming a global biotech

...was a chemist with a Ph.D. from Rutgers University...
BioCentury | May 9, 2020
Product Development

FDA authorizes first COVID-19 test using at-home saliva samples, begins unveiling serological test validation data

...FDA’s authorization of a COVID-19 diagnostic from Rutgers University marks the first time the agency has signed...
...coronavirus crisis can be found at https://www.biocentury.com/coronavirus Karen Tkach Tuzman, Associate Editor U.S. Food and Drug Administration (FDA) Rutgers University Sherlock...
BioCentury | Apr 14, 2020
Product Development

COVID-19 roundup: Can-Fite repurposing RA therapy; plus Brazilian chloroquine study points to cardiotoxicity, Athersys stem cell trial, Rutgers saliva test

...Rutgers spit test authorized FDA granted Emergency Use Authorization (EUA) to a COVID-19 test from Rutgers University...
...receptor Elizabeth S. Eaton, Staff Writer and Sandi Wong, Assistant Editor MultiStem (Multipotent adult progenitor cells (MAPC)) Athersys Inc. Rutgers University Can-Fite...
BioCentury | Feb 1, 2020
Distillery Therapeutics

SNCA mRNA-binding compound for Parkinson's

...Natl. Acad. Sci. USA ; published online Jan. 3, 2020 doi:10.1073/pnas.1905057117 CONTACT: M. Maral Mouradian, Rutgers University...
...N.J. email: m.mouradian@rutgers.edu CONTACT: Matthew D. Disney, The Scripps Research Institute, Jupiter, Fla. email: disney@scripps.edu Claire Quang Rutgers University Scripps...
BioCentury | Jan 30, 2020
Distillery Therapeutics

Flu vaccines as a cancer immunotherapies

...CONTACT: Andrew Zloza, Rush University Medical Center, Chicago, Ill.; Rutgers University, New Brunswick, N.J. email: Andrew_Zloza@rush.edu Claire Quang Rutgers University Rush...
BioCentury | Feb 9, 2019
Company News

Emerging company roundup: HiberCell, Orexia, TamRx

...from pharmaceutical accelerator BioMotiv LLC. The cancer immunotherapy company, which is based on research from Rutgers University...
BioCentury | Feb 8, 2019
Company News

BioMotiv, Rutgers launch TamRx

...the clinic with its pan-TAM inhibitors in 2021. The company is based on research from Rutgers University...
...TYRO3 protein tyrosine kinase TamRx LLC, Cleveland, Ohio BioMotiv LLC, Cleveland, Ohio Business: Cancer Mark Zipkin BioMotiv LLC Rutgers University AXL...
BioCentury | Feb 7, 2019
Company News

BioMotiv, Rutgers launch TamRx

...the clinic with its pan-TAM inhibitors in 2021. The company is based on research from Rutgers University...
...6; MERTK - c-Mer proto-oncogene tyrosine kinase; TYRO3 (Sky) - TYRO3 protein tyrosine kinase Mark Zipkin BioMotiv LLC Rutgers University AXL...
Items per page:
1 - 10 of 79